drugset / Trial / NCT06119529

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

NCT06119529

Phase 1 Terminated 18 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healthy participants. The study is conducted in three parts (part A, B and C). The study will last up to approximately 85, 183 and 44 days for parts A, B, and C, respectively.

Timeline

Start
2023-11-01
Primary completion
2024-04-08
Completion
2024-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3872386 Unknown Intravenous
Subject Prednisone Other / unclassified Oral

Indications